TABLE 2.
Results of the univariate analysis.
| Characteristics | Number of patients | Median PFS | p-value | HR (95% CI) |
|---|---|---|---|---|
| Months (95% CI) | ||||
| Gender | ||||
| Male | 19 | 6.1 (3.1, 9.2) | 0.76 | 1.14 (0.50, 2.62) |
| Female | 12 | 4.2 (2.7, 5.7) | — | — |
| Age | ||||
| ≥42 years | 17 | 4.6 (2.7, 6.5) | 0.93 | 1.04 (0.47, 2.28) |
| <42 years | 14 | 4.2 (3.1, 5.3) | — | — |
| KPS score | ||||
| ≥60 | 20 | 6.7 (3.7, 9.6) | <0.001 | 0.18 (0.068, 0.481) |
| <60 | 11 | 3.3 (2.5, 4.0) | — | — |
| Histology | ||||
| Grade 4 | 21 | 4.5 (3.1, 5.8) | 0.70 | 1.18 (0.52, 2.68) |
| Grade 3 | 10 | 4.6 (1.6, 7.6) | — | — |
| Tumor location | ||||
| Multifocal/dissemination | 22 | 3.2 (2.7, 3.8) | 0.009 | 3.23 (1.27, 8.21) |
| Focal | 9 | 8.1 (6.3, 9.9) | — | — |
| MGMT promoter status | ||||
| Methylation | 12 | 6.1 (2.0, 10.3) | 0.35 | 0.68 (0.31, 1.53) |
| unmethylation | 19 | 4.5 (2.6, 6.3) | — | — |
| IDH status | ||||
| Mutation | 9 | 6.1 (0.48, 11.8) | 0.49 | 0.74 (0.31, 1.74) |
| Wild type | 22 | 4.5 (3.1, 5.8) | — | — |
| Previous anti-angiogenesis | ||||
| Yes | 13 | 3.3 (2.4, 4.1) | 0.044 | 2.2 (1.00, 4.83) |
| No | 18 | 6.1 (2.8, 9.5) | — | — |
| Study treatment | ||||
| Anlotinib plus TMZ | 14 | 6.1 (3.0, 9.2) | 0.29 | 0.66 (0.30, 1.44) |
| Anlotinib | 17 | 4.2 (2.4. 6.0) | — | — |
KPS, Karnofsky Performance Status score; MGMT, O6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; TMZ, temozolomide.